Latest stories on PRQR
ProQR Doses First Participant in Phase 1 Trial of AX-0811 for Cholestatic Liver Diseases
TipRanks63 · neutralproduct/pr
ProQR Therapeutics doses first participant in AX-0811 clinical trial
The Fly63 · neutralproduct/pr
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
GlobeNewswire63 · neutralproduct/pr
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
Business Insider63 · neutralproduct/pr
ProQR to Participate in Upcoming Investor Conferences in September 2026
Business Insider56 · neutralgeneral
ProQR to Participate in Upcoming Investor Conferences in September 2026
GlobeNewswire56 · neutralgeneral
ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts
Seeking Alpha67 · bullishanalyst
ProQR a new buy at BoA on RNA-editing platform
Seeking Alpha63 · neutralanalyst
ProQR Therapeutics initiated with a Buy at BofA
The Fly61 · neutralanalyst
ProQR GAAP EPS of -€0.08, revenue of €8.76M
Seeking Alpha34 · bearishearnings
ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis
Seeking Alpha67 · bullishproduct/pr
ProQR prices $50M stock offering; secures $9.2M investment from Eli Lilly
Seeking Alpha28 · bearishgeneral
ProQR posts early-stage trial data for liver disease candidate
Seeking Alpha63 · neutralproduct/pr
ProQR Reports Positive Phase 1 Data Validating Axiomer RNA Editing Platform
TipRanks73 · bullishproduct/pr
ProQR Therapeutics N.V. (PRQR) Presents at 29th ASGCT Annual Meeting 2026 - Slideshow
Seeking Alpha50 · neutralgeneral
ProQR Therapeutics N.V. (PRQR) Presents at TIDES USA 2026 - Slideshow
Seeking Alpha50 · neutralgeneral